Related Experiment Video
Updated: Apr 22, 2026

Analysis of mRNA Nuclear Export Kinetics in Mammalian Cells by Microinjection
Published on: December 4, 2010
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents
Kaushal Parikh, Shundong Cang, Arunabh Sekhri
1Henan Tumor Hospital, Zhengzhou University, Zhengzhou, China. Delong_liu@nymc.edu.
Abstract:
Dysregulation of the nucleo-cytoplasmic transport of proteins plays an important role in carcinogenesis. The nuclear export of proteins depends on the activity of transport proteins, exportins. Exportins belong to the karyopherin β superfamily. Exportin-1 (XPO1), also known as chromosomal region maintenance 1 (CRM1), mediates transport of around 220 proteins. In this review, we summarized the development of a new class of antitumor drugs, collectively known as selective inhibitors of nuclear export (SINE). KPT-330 (selinexor) as an oral agent is showing activities in early clinical trials in both solid tumors and hematological malignancies.
Insights
Selective inhibitors of nuclear export (SINE) target Exportin-1 (XPO1) to disrupt cancer cell growth. The drug KPT-330 (selinexor) shows promise in early trials for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Nucleo-cytoplasmic transport is crucial for cellular function and its dysregulation is implicated in cancer.
- Exportins, particularly Exportin-1 (XPO1/CRM1), are key regulators of protein nuclear export.
- XPO1 mediates the transport of over 200 proteins, influencing cell proliferation and survival.
Purpose of the Study:
- To review the development and therapeutic potential of selective inhibitors of nuclear export (SINE) drugs.
- To highlight the role of XPO1 as a therapeutic target in oncology.
- To discuss the clinical progress of KPT-330 (selinexor) in treating malignancies.
Main Methods:
- Literature review of studies on nucleo-cytoplasmic transport, XPO1, and SINE compounds.
- Summary of preclinical and clinical data for SINEs, focusing on KPT-330.
- Analysis of the mechanism of action of XPO1 inhibitors.
Main Results:
- Selective inhibitors of nuclear export (SINE) represent a novel class of anticancer agents.
- KPT-330 (selinexor) has demonstrated promising activity in early-phase clinical trials.
- SINEs target the XPO1-mediated nuclear export pathway, impacting cancer cell viability.
Conclusions:
- Targeting XPO1 with SINEs offers a promising therapeutic strategy for cancer treatment.
- KPT-330 (selinexor) is an orally available agent with potential applications in both solid tumors and hematological malignancies.
- Further clinical investigation is warranted to establish the efficacy and safety of SINEs in diverse cancer types.
More Related Videos
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Nuclear Protein Sorting
Proteins targeted to the nucleus carry nuclear localization signals or NLS recognized by import receptors in the cytosol. Similarly, proteins with nuclear export signals are recognized by export receptors. Import and export receptors are...
Nuclear Export of mRNA
Nuclear Export of mRNA
Regulation of Nuclear Protein Sorting
Nuclear Localization Signals and Import

